The International Trifecta<sup>TM</sup> and Epic<sup>TM</sup> Valve‐in‐Valve Registry: Insights Into Clinical & Hemodynamic Outcomes
Compared to a stented prosthesis without increased risk of CO, ViV-TAVR into Trifecta prostheses can be performed with low risk of CO and acceptable short-term clinical outcomes. As the rate of post-ViV PPM is substantial for both prostheses, careful patient selection is warranted. (NCT05389631).
Authors
- Manuel Wilbring (ORCID: https://orcid.org/0000-0002-3382-1142)
- Matthias Raschpichler (ORCID: https://orcid.org/0000-0003-0087-7972)
- Nick Curzen (ORCID: https://orcid.org/0000-0001-9651-7829)
- Hölger Thiele (ORCID: https://orcid.org/0000-0002-0169-998X)
- Mohamed Abdel Wahab (ORCID: https://orcid.org/0000-0003-0004-6036)
- Kayan Lam
- C. Dubois (ORCID: https://orcid.org/0000-0001-8307-8337)
- Michael A. Borger (ORCID: https://orcid.org/0000-0003-0780-6851)
- Gloria Faerber
- Jana Nagel
Institutions
- Radboud University Nijmegen (NL)
- Catharina Ziekenhuis (NL)
- University Hospital Southampton NHS Foundation Trust (GB)
- Essex Cardiothoracic Centre (GB)
- Leipzig Heart Institute (DE)
- Jena University Hospital (DE)
- University Hospital Carl Gustav Carus (DE)
Publication Details
- Journal
- Catheterization and Cardiovascular Interventions
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1002/ccd.31492
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00